Publications by authors named "E Zavadova"
Article Synopsis
- The study assessed the prognostic value of the Immunoscore in Stage I/II colon cancer patients, using data from over 1,800 individuals across North America and Europe.
- Results indicated that a high Immunoscore correlated with lower recurrence rates and better survival outcomes, especially significant in Stage II and high-risk Stage II patients.
- The findings suggest that a low Immunoscore can effectively identify early colon cancer patients at risk of relapse, even when accounting for other clinical factors.
BACKGROUND: In this study, we evaluated the prognostic value of Immunoscore in patients with stage I−III colon cancer (CC) in the Asian population. These patients were originally included in an international study led by the Society for Immunotherapy of Cancer (SITC) on 2681 patients with AJCC/UICC-TNM stages I−III CC. METHODS: CD3+ and cytotoxic CD8+ T-lymphocyte densities were quantified in the tumor and invasive margin by digital pathology.
View Article and Find Full Text PDFTo evaluate the effect of pleuran (β-glucan from ) administration on the immune profile of patients with endocrine-dependent breast cancer (clinical stages I-II) in clinical and imaging remission. Antitumor cellular immunity (CD19, CD3, CD4 and CD8 T lymphocytes and natural killer cells) of 195 patients (49 in the pleuran group and 146 in the control group) was measured by flow cytometry. We observed a significant increase in the absolute number of CD3, CD19, CD4 and CD8 T lymphocytes in the pleuran group compared with the control group.
View Article and Find Full Text PDFPurpose: The purpose of this study was to evaluate the prognostic value of Immunoscore in patients with stage III colon cancer (CC) and to analyze its association with the effect of chemotherapy on time to recurrence (TTR).
Methods: An international study led by the Society for Immunotherapy of Cancer evaluated the predefined consensus Immunoscore in 763 patients with American Joint Committee on Cancer/Union for International Cancer Control TNM stage III CC from cohort 1 (Canada/United States) and cohort 2 (Europe/Asia). CD3+ and cytotoxic CD8+ T lymphocyte densities were quantified in the tumor and invasive margin by digital pathology.
Background: The objective of this study was to investigate serum levels of immunosuppressive cytokines TGF beta 1 and VEGF and count of immune cells in peripheral blood in stage II and III colorectal cancer patients.
Methods: Blood samples were collected from 22 colorectal patients and 25 healthy controls before the start of treatment. All patients were examined by a clinical immunologist to exclude patients with immune disorders and autoimmune diseases.